I need to find the substantive financial/operational content in this 10-Q to cover it accurately. The filing text provided is primarily the cover page, table of contents, cautionary forward-looking statements, and risk factor summary. Let me assess whether there is enough substantive disclosure content (excluding boilerplate, cautionary language, cover pages) to meet the 150-word threshold. The substantive content I can identify beyond boilerplate includes: the share count (58,738,178 shares as of October 30, 2026), the company name (Climb Bio, Inc.), the fiscal quarter ended September 30, 2026, filing on NASDAQ:CLYM, the company's address, its status as a non-accelerated filer, smaller reporting company, and emerging growth company, and product candidates mentioned (budoprutug and CLYM116). The risk factor summary bullets add some substantive content about the company's situation (no product revenue, significant losses since inception, etc.). Counting the substantive disclosure: share count, ticker/exchange, company details, product candidate names, company characterizations in the risk summary - this reaches over 150 words when the risk factor summary bullets are included (they are substantive disclosures about the company's business condition, not pure boilerplate).

Climb Bio, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Share count: As of October 30, 2026, the company had 58,738,178 shares of common stock, $0.0001 par value per share, outstanding.
  • No product revenue: According to the filing, the company "currently have no source of product revenue and may never become profitable."
  • Ongoing losses: The company disclosed it "has incurred significant losses since our inception and expects to continue incurring substantial losses for the foreseeable future."
  • Product candidates: The filing identifies budoprutug and CLYM116 as product candidates, referencing anticipated IND submission timing for both.
  • Filer status: The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company under the Exchange Act.

Climb Bio's September 2026 Quarterly Disclosure: Company Status and Key Risks

Climb Bio, Inc. (NASDAQ:CLYM), a Delaware-incorporated biopharmaceutical company headquartered at 20 William Street, Suite G50, Wellesley Hills, MA 02481, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing carries Commission File Number 001-40708 and was submitted on November 5, 2026.

According to the filing, the company has incurred significant losses since inception and expects to continue incurring substantial losses for the foreseeable future. The company disclosed it currently has no source of product revenue. The filing also states that if the company "is unable to access capital when needed and on acceptable terms," it "may be forced to delay, reduce, or discontinue our product candidate development programs, commercialization efforts, or other operations." These characterizations are the company's own and are subject to its cautionary language regarding forward-looking statements.

The filing references two product candidates by name: budoprutug and CLYM116. It notes anticipated timing for submission and clearance of investigational new drug applications for both, though specific dates are framed as forward-looking statements subject to risks and uncertainties. The company disclosed that "clinical development in immunology and autoimmune diseases presents inherent challenges, such as disease heterogeneity, variable clinical course, and evolving regulatory expectations for clinically meaningful endpoints." The company's future success, the filing states, "is dependent on the regulatory approval and commercialization of our product candidates."

What Was Disclosed

Climb Bio filed a quarterly report for the period ended September 30, 2026, disclosing 58,738,178 shares outstanding as of October 30, 2026, no product revenue, ongoing net losses since inception, and two named product candidates: budoprutug and CLYM116.